GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Pangaea Oncology SA (XMAD:PANG) » Definitions » EV-to-Revenue

Pangaea Oncology (XMAD:PANG) EV-to-Revenue : 5.11 (As of Jun. 03, 2025)


View and export this data going back to 2016. Start your Free Trial

What is Pangaea Oncology EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Pangaea Oncology's enterprise value is €62.64 Mil. Pangaea Oncology's Revenue for the trailing twelve months (TTM) ended in Jun. 2024 was €12.26 Mil. Therefore, Pangaea Oncology's EV-to-Revenue for today is 5.11.

The historical rank and industry rank for Pangaea Oncology's EV-to-Revenue or its related term are showing as below:

XMAD:PANG' s EV-to-Revenue Range Over the Past 10 Years
Min: 6.03   Med: 9.2   Max: 14.61
Current: 5.11

During the past 11 years, the highest EV-to-Revenue of Pangaea Oncology was 14.61. The lowest was 6.03. And the median was 9.20.

XMAD:PANG's EV-to-Revenue is ranked worse than
70.33% of 209 companies
in the Medical Diagnostics & Research industry
Industry Median: 2.75 vs XMAD:PANG: 5.11

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2025-06-03), Pangaea Oncology's stock price is €1.73. Pangaea Oncology's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2024 was €0.40. Therefore, Pangaea Oncology's PS Ratio for today is 4.28.


Pangaea Oncology EV-to-Revenue Historical Data

The historical data trend for Pangaea Oncology's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pangaea Oncology EV-to-Revenue Chart

Pangaea Oncology Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.65 8.72 8.09 9.20 6.03

Pangaea Oncology Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 9.20 - 6.03 -

Competitive Comparison of Pangaea Oncology's EV-to-Revenue

For the Diagnostics & Research subindustry, Pangaea Oncology's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pangaea Oncology's EV-to-Revenue Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Pangaea Oncology's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Pangaea Oncology's EV-to-Revenue falls into.


;
;

Pangaea Oncology EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Pangaea Oncology's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=62.644/12.259
=5.11

Pangaea Oncology's current Enterprise Value is €62.64 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Pangaea Oncology's Revenue for the trailing twelve months (TTM) ended in Jun. 2024 was €12.26 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pangaea Oncology  (XMAD:PANG) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Pangaea Oncology's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=1.73/0.404
=4.28

Pangaea Oncology's share price for today is €1.73.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Jun. 2024 was €0.40.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pangaea Oncology EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Pangaea Oncology's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Pangaea Oncology Business Description

Traded in Other Exchanges
N/A
Address
Calle Sabino Arana, 5-19, Barcelona, ESP, 08028
Pangaea Oncology SA is a medical services company. The company provides a wide range of services to cancer patients, as well as global pharmaceutical and biotech clients, in the fields of molecular diagnostics, clinical trials, in vitro drug profiling, dx platform validation, and biomarker discovery. The company has aggregated its operations into two segments, Clinical Care division and Diagnostic and Research and Development services division. Clinical Care division delivers medical oncology services and related activities. Diagnostic and Research and Development services division provides diagnostic and in-vitro services.

Pangaea Oncology Headlines

No Headlines